As the EAS5 was about one hundred times more potent than THL and exerted most of its multi-targeting effects against NB4 cells, it may be considered as a candidate for future clinical trial of complementary APL treatment. The gene discussed is TCHH; the disease is acute promyelocytic leukemia.